Archer Materials Limited shows a textbook contradiction: AXE.AX has slid from A$0.32 to A$0.30 across recent sessions yet outperforms the ASX All Ordinaries by more than 25% over six months. This piece cuts through the noise: real verified prices, what analysts are actually saying, and whether the quantum story adds up for your portfolio.

4 related posts

Current Price: AU$0.30 · Change: -1.64% · Exchange: ASX:AXE · Focus: Quantum Materials · Top Source: ASX.com.au

Quick snapshot

1Confirmed facts
2What’s unclear
3Timeline signal
  • 2026 flagged as inflection year for 12CQ quantum chips (Stocks Down Under)
  • Sell signal from pivot top on July 21, 2025 (StockInvest)
  • Biochip commercialization challenges persist (HelloStake)
4What’s next

The table below consolidates the most critical price and company data into a single reference point.

Metric Value
Ticker ASX:AXE
Company Archer Materials Limited
Latest Price AU$0.30
Change -0.0050 (-1.64%)
Primary Source ASX.com.au

Is Axe a buy?

The honest answer hinges on your tolerance for risk and your faith in unproven technology. Most recent analyst coverage lands on a Sell rating with a price target of A$0.28, according to Perplexity Finance—meaning the consensus thinks the stock is already priced above what fundamentals justify, at least in the near term. That headline masks a more nuanced picture, though.

Current analyst consensus

The analyst picture for AXE.AX is thin. Stockopedia reports no formal analyst target prices are currently available from major brokerages, and the handful of available ratings lean negative. The Sell call tied to a A$0.28 target reflects skepticism about near-term revenue prospects, which makes sense when you consider the company is still developing quantum computing components that haven’t yet reached commercial scale.

What’s notable is that the technical picture tells a different story. The 200-day moving average comparison from Stockopedia shows AXE.AX closing at AU$0.35 recently, sitting 8.27% above that long-term average—a sign that price momentum has been working in the stock’s favor even as analyst sentiment stays cautious.

Recent price performance

Verified closing data paints a volatile near-term picture. AXE.AX moved from A$0.32 on March 30 to A$0.31 on March 31, then dropped to A$0.30 on April 1, 2026, with each session showing declines around 3%, per Motley Fool Australia. The stock’s AU$0.30 price as of April 23, down 1.64%, according to Stockopedia, reflects continued softness.

The upshot

The divergence between technical strength and weak analyst sentiment is the key tension here. Momentum traders have been rewarded; fundamental investors are waiting for proof the quantum chips can generate real revenue.

Archer Materials Stock Price Forecast. Should You Buy AXE.AX?

Forecasts for a penny-stock quantum play are all over the map—and that’s being generous. The further out you look, the wilder the projections swing, which tells you something important before you scroll further.

Short-term predictions

Short-term forecasting services paint a cautious picture. WalletInvestor projects AXE.AX around A$0.4041 by late October 2025, with a range between A$0.378 and A$0.428, according to their platform data. That’s a bullish view, but it’s worth noting WalletInvestor also forecasts a potential drop from A$0.390 to A$0.2099—a swing of roughly 46% in the other direction.

StockInvest’s technical model, cited on their analysis page, predicts a short-term decline of 19.89% over the next three months, with prices potentially settling between A$0.217 and A$0.314. A sell signal was already triggered from a pivot top on July 21, 2025, and the stock had fallen 8.06% from that point.

Long-term outlook

Long-term forecasts on the OTC equivalent ARRXF are jaw-dropping in both directions. StockScan’s forecast data shows 12-month projections averaging A$0.0781 (down 71.50% from current levels) but 2040 targets averaging $1.8847—a gain of nearly 670%. By 2050, the model projects $3.4105. These are tier3 forecasting services with low confidence; treat them as speculative noise rather than actionable data.

Why this matters

When you see a service forecast $3.41 by 2050 but $0.03 in 30 days, you know the models are unstable. Long-term quantum potential may be real, but it doesn’t guarantee orderly intermediate pricing.

What problem does Archer Materials solve?

Understanding what Archer Materials actually does matters more than the share price noise. The company is working on two parallel technology bets: a quantum computing chip project called 12CQ and a biochip platform for medical diagnostics.

Quantum readout challenge

Quantum computers require precise control and measurement of quantum bits (qubits), and one of the persistent engineering hurdles is “quantum readout”—detecting the state of a qubit without disturbing it. Archer Materials claims progress on this front, positioning itself as a component supplier to larger quantum computing efforts rather than a full-stack quantum computer builder. The 2026 timeline from Stocks Down Under flags this as an inflection year, but “progress” and “commercial revenue” are still separated by significant uncertainty.

Core technology

The biochip side targets the “lab-on-a-chip” market—miniaturized diagnostic devices that can run blood tests or other assays in compact, portable formats. HelloStake’s analysis notes that while positive news sent AXE.AX up more than 11% on a recent session, the company faces real challenges in turning lab demonstrations into manufacturable products at scale. Some investors categorize Archer Materials as speculative precisely because the financial position remains weak, per the same HelloStake assessment.

What this means

A single-session 11% jump signals that traders are willing to bet on unproven tech, but those gains disappear if lab demonstrations fail to translate into scalable manufacturing.

Upsides

  • Outperformed ASX All Ordinaries by +25.46% over 6 months (Stockopedia)
  • Healthy finances and global partnerships support long-term runway (Stocks Down Under)
  • Positive MACD buy signal suggests short-term momentum (StockInvest)
  • Trading above 200-day moving average shows sustained bullish trend

Downsides

  • Analyst consensus: Sell rating with A$0.28 target—below current price (Perplexity Finance)
  • PE ratio null—no earnings to justify valuation on traditional metrics
  • Commercialization challenges on biochip remain unresolved
  • High risk classification due to volatility and wide Bollinger Bands

Axe share price history

The trading history tells a story of a stock that rewards patience and punishes impulse. Over the past year, the price has swung without a clear directional trend, but the six-month view shows genuine strength relative to the market.

Key price milestones

Verified data from Motley Fool Australia and Stockopedia shows the following confirmed closing prices: A$0.32 on March 30, 2026; A$0.31 on March 31, 2026; A$0.30 on April 1, 2026; and AU$0.30 on April 23, 2026. Earlier in 2025, the stock fell 5.00% to A$0.285 on July 23 following a sell signal from a pivot top, per StockInvest’s technical analysis.

Trading charts

Simply Wall St’s volatility assessment describes AXE.AX as having a stable share price with low volatility over the past three months relative to the Australian market overall. This contrasts with StockInvest’s high-risk classification citing wide Bollinger Band prediction intervals—a reminder that different analytical tools reach different conclusions from the same price data.

The catch

Low volatility versus the index sounds reassuring until you remember this is a speculative tech play. The stability may reflect low liquidity as much as investor calm.

Axe share price prediction

Making a price prediction on a quantum-tech microcap is essentially attempting to put a number on hope. Here’s what we can say with reasonable confidence versus what rests on fragile assumptions. For those interested in the latest updates, the 2024 Toyota Prado price provides detailed information.

Analyst targets

The most concrete analyst anchor comes from the Sell rating at A$0.28 per share, published by Perplexity Finance. This represents the sole formal analyst target visible in available coverage—a thin data set that investors should supplement with their own due diligence rather than treating as a broad consensus. Stockopedia’s platform confirms no official analyst price targets from major investment banks are currently listed.

Market factors

Several inputs will drive near-term price movement. Support sits near A$0.280 from accumulated volume, while short-term resistance clusters around A$0.299 (the 50-day moving average), with longer-term resistance at A$0.265, per StockInvest. A break above A$0.299 would be technically significant. The quantum sector remains sensitive to broader tech-risk sentiment, meaning rate decisions from the RBA and macro headwinds can move AXE.AX in ways unrelated to company-specific progress.

“The most recent analyst rating on Archer Materials stock is a Sell with a price target of A$0.28, reflecting deep skepticism about near-term revenue prospects.”

— Perplexity Finance, Analyst Summary

“Archer’s progress with quantum chips and biochip tech, combined with their healthy finances, make them a compelling option for investors who want to back groundbreaking technologies.”

— Stocks Down Under, Investment Analysis

“Some investors dismiss Archer materials as a speculative investment and cite a weak financial position as a reason not to buy.”

— HelloStake, Brokerage Platform

For Australian investors weighing a quantum-tech gamble, the calculus is straightforward: the current analyst consensus of Sell at A$0.28 sits below today’s A$0.30 price, making the technical case harder to ignore.

Related reading: WTC Share Price – Live ASX Quote, Charts and Analysis

While Axe holds steady around AU$0.30 amid quantum tech buzz, the KGN.AX forecast analysis spotlights Kogan’s divided analyst views on near-term upside.

Don't miss these

Frequently asked questions

What is the current AXE share price?

As of the most recent data, AXE.AX trades at AU$0.30 on the ASX, down 1.64% in the latest session. Verified closing prices from Motley Fool Australia show A$0.30 on April 1, 2026.

Where can I view AXE announcements?

Official company announcements are available directly from the ASX company page, which provides the authoritative record of all price-sensitive releases.

What is Archer Materials’ market cap?

Market cap for Archer Materials is calculated by multiplying the share price by shares outstanding. With AXE.AX at AU$0.30 and the company’s share count, the market cap positions it as a small-cap speculative listing on the Australian market.

How volatile is AXE stock?

Assessment varies by source. Simply Wall St describes volatility as low relative to the Australian market over three months, while StockInvest classifies it as high-risk given wide Bollinger Band prediction intervals. Reality likely sits between those two characterizations.

What drives AXE price changes?

Near-term price action responds to news on quantum chip progress, biochip commercialization updates, broader tech sector sentiment, and general ASX small-cap risk appetite. The stock lacks the earnings floor that stabilizes larger companies.

Is AXE listed on ASX?

Yes. AXE.AX trades on the Australian Securities Exchange under ticker code AXE. The official ASX listing page is at ASX.com.au.

Who covers AXE analyst ratings?

Formal analyst coverage is sparse. The most visible rating is a Sell from Perplexity Finance with a A$0.28 target. No major investment banks currently list official price targets on AXE.AX, per Stockopedia.

What are the support and resistance levels?

Based on technical analysis from StockInvest, support sits near A$0.280 from accumulated volume. Short-term resistance clusters at A$0.299 (50-day MA) with longer-term resistance at A$0.265.

Momentum has been impressive over six months, but that momentum lacks an earnings foundation. The 2026 inflection year for 12CQ and Biochip is real—and if it materializes, today’s price will look like a bargain. If it doesn’t, there’s significant downside from a stock trading near its 200-day average without revenue to show for it.